44
Participants
Start Date
July 24, 2020
Primary Completion Date
May 4, 2021
Study Completion Date
May 4, 2021
VX-864
Tablets for oral administration.
Placebo
Placebo matched to VX-864 for oral administration.
University of Florida, Gainesville
Temple University Hospital, Philadelphia
Inova Fairfax Medical Campus, Falls Church
Wake Forest University Baptist Medical Center, Winston-Salem
University of North Carolina Medical Center, Chapel Hill
Medical University of South Carolina, Charleston
Central Florida Pulmonary, Orlando
University of Miami Miller School of Medicine, Miami
University of Alabama at Birmingham, Birmingham
University of Cincinnati, Cincinnati
The University of Iowa Hospitals and Clinics, Iowa City
University of Minnesota, Minneapolis
Cardinal Glennon Children's Hospital - St. Louis University, St Louis
Blessing Corporate Services, Inc., dba Blessing Health System, Hannibal
University of Kansas Medical Center, Kansas City
The University of Texas Health Science Center at Tyler, Tyler
Renovatio Clinical, Houston
National Jewish Health, Denver
University of Utah Health, Salt Lake City
David Geffen School of Medicine at UCLA, Los Angeles
University of California Davis Medical Center, Sacramento
Oregon Health & Science University, Portland
Queen Elizabeth II Health Sciences Center, Halifax
Inspiration Research Ltd, Toronto
University Hospital RWTH Aachen, Aachen
Universitätsklinikum Essen, Essen
Medizinische Hochschule Hannover, Hanover
Royal College of Surgeons in Ireland Clinical Research Centre, Beaumont Hospital, Beaumont
Skanes Universitetssjukhus, Malmo, Malmo
Staploe Medical Centre, Soham Ely
Vertex Pharmaceuticals Incorporated
INDUSTRY